News and Events

FDA grants breakthrough therapy designation for new CAR T-cell therapy for B-cell acute lymphoblastic leukemia

In August 2019, the U.S. Food and Drug Administration granted breakthrough therapy designation to an experimental immunotherapy being developed in the Center for Cancer Research (CCR) for the treatment of B-cell acute lymphoblastic leukemia (ALL), a type of blood cancer. The designation will advance CCR’s development and testing of an immunotherapy for children and young adults whose B-cell ALL is resistant to CD19-targeted immunotherapies.

Clinical trial evaluates dual drug therapy for untreated follicular lymphoma

Follicular lymphoma (FL) is a cancer of white blood cells (B cells) that help your body fight infections. Investigators are leading a clinical trial at the NIH Clinical Center to see if a combination therapy can slow the growth of FL in patients who have not received prior treatment.

Steve Rosenberg receives 2019 Edogawa NICHE Prize

Steve Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, has received the 2019 Edogawa NICHE Prize. Dr. Rosenberg was recognized for his pioneering work in developing effective adoptive immunotherapies and genetically modified T cells, which has heralded the birth of a new chapter in the fight against cancer.

James Kochenderfer named finalist for 2019 FNIH Trailblazer Prize for Clinician-Scientists

James N. Kochenderfer, M.D., Investigator in the Surgery Branch, has been selected as a finalist for the Foundation for the National Institutes of Health (FNIH) Trailblazer Prize for Clinician-Scientists. He is nominated for developing immunotherapies that leverage chimeric antigen receptor (CAR) T cells to treat blood cancers, including lymphoma and multiple myeloma. The winner of the Trailblazer Prize will be announced October 23, 2019.

Clinical Trial Conversation: Tim Greten describes primary liver cancer clinical trial

Hepatocellular carcinoma (HCC) is an aggressive form of liver cancer that is very difficult to treat, and patients live an average of six to nine months after diagnosis. Tim Greten, M.D., Deputy Chief of the Thoracic and GI Malignancies Branch, is leading a new clinical trial to determine whether administering the antibiotic vancomycin in combination with the drugs nivolumab and tadalafil will lead to cancer regression in patients with liver metastasis or primary HCC.

Bill Telford receives 2019 International Society for the Advancement of Cytometry Distinguished Service Award

Bill Telford, Ph.D., Senior Associate Scientist in the Experimental Transplantation and Immunology Branch, has received the 2019 International Society for the Advancement of Cytometry (ISAC) Distinguished Service Award. The award honors individuals who served ISAC in a major role, provided major support to ISAC and its members or made a significant contribution to the success of ISAC.

Contour maps created from glucose and lactate signals

Researchers develop a new imaging technique to measure cancer metabolism

CCR researchers have developed a new technique to show metabolism from MRI images by reducing the amount of noise in those images, resulting in significantly improved quality. This breakthrough enables researchers to see biochemical processes, paving the way for a deeper understanding of tumors and potentially improved diagnosis and treatment.

Jack Shern featured in LocalDVM news article

Jack Shern M.D., Investigator in the Pediatric Oncology Branch, was recently featured in a LocalDVM news article focused on Camp Fantastic, a week-long camp for children with cancer. In the article, Dr. Shern discusses his role as medical director of the camp and medical services provided to campers.

New clinical trial tests CAR T-cell therapy for multiple myeloma

James N. Kochenderfer, M.D., Investigator in the Surgery Branch, is leading a study of a new way to treat multiple myeloma (MM) that uses a patient’s own T cells to target MM cells. MM is a rare blood cancer that occurs in blood, tissues, bone and bone marrow. With MM, a group of plasma cells become cancerous and multiply, crowding out healthy blood cells.

Clinical trial tests combination therapy in untreated aggressive B-cell lymphomas

The Lymphoid Malignancies Branch is leading a study of a combination therapy for aggressive B-cell lymphomas using a drug that interferes with the activity of an enzyme that plays a crucial role in the development of B cells and in the cellular signaling that allows cancerous cells to multiply and survive.

Breadcrumb